UiPath stock price forecast: Bullish catalysts offset by selling pressure as PATH falls 6.50%

Traders Union
All News
Financial News
UiPath slides 6.50% to $11.58 today

Highlights

UiPath exceeded Q4 revenue expectations at $481 million and achieved its first full-year GAAP operating profit of $57 million.
Fiscal 2027 guidance topped consensus, supported by new AI automation launches, WorkFusion integration, and a fresh $500 million buyback authorization.
Despite strong results, technical signals remain bearish with intense recent volatility, limited rebound potential, and a likely $11.00–$11.99 trading range ahead.

Earnings outperformance and AI push as shares face selling pressure

On Wednesday, UiPath reported fourth quarter revenue of $481 million, surpassing analyst estimates and achieving annual recurring revenue of $1.853 billion with an 11% year-over-year increase. The company posted its first full-year GAAP operating profit of $57 million for fiscal 2026 and authorized a new $500 million stock repurchase plan after completing a prior $1 billion buyback. Fiscal year 2027 revenue guidance was provided above consensus, accompanied by the launch of agentic AI automation solutions, completion of the WorkFusion acquisition, and securing AIUC-1 certification for secure AI agents, though price action has remained under broader selling pressure.

Volatility and pullback risks as overbought signals diverge

Technical signals are mixed for PATH. The Ichimoku Kijun on D1 stands at $11.41, just below current levels and acting as near-term support. MACD on D1 reflects strong selling pressure, with ADX pointing to a moderately strong bearish trend. Among oscillators, the RSI is modestly bullish on D1, but both the CCI and Stoch RSI are in overbought territory, warning of pullback risks. BBP recently showed a buyer advantage, yet today's 6.50% decline, following a sharp gap down and partial recovery, underscores ongoing volatility and divergences between overbought oscillators and downside action, suggesting possible near-term exhaustion.

Sideways outlook favored as limited upside meets bearish technicals

The expected 5-day range for PATH is $11.00 to $11.99, capturing the typical volatility band relative to current levels. Short-term upside potential is limited, with less than a 20% probability of a price increase in the coming week given the persistent bearish signals from weekly moving averages, RSI, and MACD. The base case scenario is sideways movement within this corridor. A sustained bullish move would require a close above $11.99, while a decisive drop below $11.00 could lead to further downside as sellers regain momentum.

Viktoras Karapetjanc, Traders Union analyst, sees robust fundamental progress at UiPath with record recurring revenue and a new buyback authorization. However, he notes that macro sentiment remains challenging, as seen in persistent selling pressure despite positive news and guidance. The base case is a period of consolidation within the $11.00–$11.99 range, with bullish momentum needing confirmation above $11.99. He believes medium-term institutional positioning may shift if the macro backdrop stabilizes. "AI-driven automation tailwinds are strong, but we need to see the market absorb recent volatility before a sustainable upside breakout can form."

Previously it was reported that UiPath Inc PATH is trading above its short-term SMA-20 but remains below both its 50- and 200-day moving averages, reflecting lingering medium- and long-term bearish pressure despite near-term strength. Momentum indicators are mixed, with MACD signaling a strong sell, ADX suggesting weak trend conviction, and the price facing immediate support near the Kijun level and resistance at the SMA-50, as intraday volatility and selling pressure persist.

Source of Data: PATH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.